Peptides in 2TM · Eloralintide
Episode 13 · 1:53 · English
Eloralintide: selectivity, tested
Explore Eli Lilly’s eloralintide, the meaning of receptor selectivity, and published 48-week single-agent obesity results. Laboratory potency, clinical weight change, tolerability, and combination research each retain their own context.
English narration and optional captions. Captions use recognition-assisted timing with scientific terms corrected. Translated subtitles are not yet available for this episode.
Published . Evidence cutoff: October 14, 2026.
Behind the film: Eloralintide references & context
Peptides in 2 — Episode 13: Selectivity, tested. Evidence cutoff: October 14, 2026. Published October 14, 2026. World Peptide Foundation. Every experience matters.
What the film examines
This episode follows eloralintide's receptor-selectivity design and its 48-week single-agent obesity trial. It does not repeat the earlier amylin-origin story, display an invented atomic complex, or rank separate medicines using results from different trials. Educational information, not medical advice. WPF does not sell peptides. Scientific studies and contributed experiences remain distinct forms of evidence.
Developer, investigators and history
Eli Lilly and Company developed eloralintide, previously designated LY3841136. Daniel A. Briere and colleagues reported discovery-to-proof-of-concept research in 2025; their listed affiliation is Eli Lilly in Indianapolis, Indiana, United States. This is an affiliation, not a claim about an exact invention room. Liana K. Billings and colleagues authored the later randomized phase 2 clinical report. Developer, discovery researchers and clinical investigators have different roles; no individual is credited as sole inventor.
Briere DA, Qu H, Lansu K, et al. Molecular Metabolism 102:102271 (2025). DOI 10.1016/j.molmet.2025.102271. PubMed 41109426; open primary article.
What selectivity means
Eloralintide is an engineered human-amylin analogue studied as a once-weekly subcutaneous medicine. In the discovery paper's human-receptor assays, it activated AMY1R approximately 12-fold more potently than CTR and 11-fold more potently than AMY3R. The film's ~12× figure refers to functional receptor potency in vitro. It is not a clinical effect-size multiplier or a promise of better tolerability. Selective does not mean exclusive: the paper reports agonism at all three tested human receptors. Assay conditions and species matter; the receptor comparison is not a measurement inside a patient. The film uses no molecular dynamics or eloralintide-binding animation.
The discovery work includes cellular, animal and early human investigations. Animal tolerability and body-composition observations are not represented as established human clinical benefits. The film's clinical weight graphic instead uses the later phase 2 report.
Published phase 2 evidence
Billings and colleagues randomized 263 adults in a 48-week, double-blind, placebo-controlled study, NCT06230523. Participants had obesity or overweight with a weight-related comorbidity and did not have type 2 diabetes. There were six active regimens and placebo. Estimated mean body-weight reductions were 9.5–20.1% across active groups and 0.4% with placebo. The efficacy estimand concerns the outcome if randomized participants remained on study intervention, permitting interruptions or modifications. It is not a guarantee for each patient or a description of all real-world treatment discontinuations.
Billings LK, Hsia S, Bays H, et al. The Lancet 406:2631–2643 (2025). DOI 10.1016/S0140-6736(25)02155-502155-5). PubMed 41207310; publisher record; trial registration.
Reading the clinical graphic
The chart shows magnitudes of estimated mean reductions at week 48. The underlying changes from baseline are negative. Each point is an exact reported estimate; horizontal stems connect it to zero. They are not confidence intervals, participant-response ranges or individual trajectories. The axis begins at zero and ends at 25%. All estimates stay fixed and fully visible throughout the scene.
| Research group | Estimated mean reduction |
|---|---|
| 1 mg | 9.5% |
| 3 mg | 12.4% |
| 6 mg | 17.6% |
| 9 mg | 20.1% |
| 6 → 9 mg escalation | 19.9% |
| 3 → 6 → 9 mg escalation | 16.4% |
| Placebo | 0.4% |
These are study-arm identifiers, not treatment or escalation instructions. The group estimates do not establish an optimal dose for an individual. A relative percent body-weight reduction differs from percentage-point HbA1c change. The film does not convert these estimates into kilograms for a hypothetical patient or imply lasting cardiovascular or mortality benefit.
The numerical table and efficacy-estimand explanation were also checked against Lilly's November 6, 2025 announcement. Company communications are identified as such and are not independent review.
Safety and interpretation
Gastrointestinal symptoms and fatigue were common, particularly in higher-dose arms. Slower escalation was associated with lower incidence of these events. This trial observation does not establish that every patient will tolerate treatment or that the selective receptor profile caused the difference. Read the complete paper for all adverse events, discontinuations, intervals and analysis details. The film presents selected evidence and gives no self-treatment guidance. Long-term safety and durability need further evidence.
Status at the cutoff
Eloralintide remains investigational. Phase 3 single-agent studies are underway; the sponsor's ENLIGHTEN-1 record identifies NCT07321886 and Phase III. Its population excludes type 2 diabetes. ClinicalTrials.gov provides the registry record. A trial's enrollment goal is planned participation, not a completed-study sample or published result. Phase progression is not regulatory approval, commercial availability or guaranteed success.
A September 30, 2026 Lilly announcement describes separate phase 2b research involving eloralintide plus tirzepatide in adults with obesity or overweight and type 2 diabetes, NCT06603571. The film does not place its combination results into the single-agent chart or attribute them to eloralintide alone. Company-reported combination evidence has its own population, regimens and safety profile. Future publications and regulatory decisions may change this account.
Original art, motion and rights
Four original images were generated specifically for Episode 13: a mass-spectrometry-inspired vacuum chamber, a fluorescence assay reader, a clinical measurement platform and a robotic biobank system. They are conceptual technology art, not photographs of Lilly facilities, actual trial instruments, study samples, experimental findings or marketed products. Optical highlights and illuminated wells are artistic choices, not measured assay data. These images provide research context and do not establish that the illustrated devices were used in these studies.
No earlier content image is reused or used as an edit target. Each new image appears in one content scene. Subtle camera movement over still art is presentation motion, not documentary footage of working machinery. The new interpretation diagram, clinical point plot and development-status panels use precise code-drawn typography and geometry. No glowing bead mechanism, spinning globe, inferred receptor structure or simulated binding is used.
The established WPF brand image recurs. This revision uses a fresh, neutral Tom narration performance generated at normal speed. The fuller original script is restored. There is no post-production speeding up or slowing down, and no time-stretching. The recording retains its natural delivery and pauses. The former silent chart gap now includes “Weight loss is only part of the picture. Tolerability matters too,” recorded with the same Tom voice preset at normal speed. All original speech samples and their recorded pace are preserved. The later scenes and captions move together to allow the transition to finish naturally.
The narrator also reads the closing in this same performance. No music, background voice, older narration or older closing audio is mixed into the export. The four artworks and scientific graphics are retained. No real researcher's voice is cloned and no paid video generation is used. Montserrat uses the included SIL Open Font License.
Delivery and verification
The published export is 113 seconds, 1920×1080, 24 fps, stereo AAC. The entire closing finishes before the picture fades: “Peptides in 2. World Peptide Foundation. Every experience matters.” English SRT and VTT captions use recognition-assisted word timestamps with names and numerical notation corrected. These are separate optional caption tracks. The transcript preserves the exact requested narration text.
Verification covers full decode, all eight narration windows in the exported soundtrack, the narration-only mix, closing completeness, unaltered recorded timing, audio duration, format, retained source-image hashes, fixed graphic values and caption bounds. Technical verification does not replace the viewer’s judgment of a synthetic voice’s perceived consistency. Source checking and technical verification are not independent human scientific review or institutional endorsement. No such endorsement is claimed.
The revised source pack includes the retained art, prompts, provenance, new narration, voice settings, brand image, production scripts, measured timing, corrected word timestamps, captions, transcript, updated plan, thumbnail, website copy and validation. Earlier narration and music files are excluded. Temporary signed URLs, upload helpers, full copyrighted publications and downloaded recognition engines are excluded. Corrections and primary-source suggestions: admin@worldpeptidefoundation.org.
Closing revision: “The next chapter depends on longer-term evidence.” precedes the WPF closing. Original speech remains at normal recorded pace; the final hold is shortened.
Read the English transcript
Eloralintide is a once-weekly amylin analogue developed by Eli Lilly. Its design asks a focused question: can receptor selectivity improve the treatment of obesity?
Daniel Briere and colleagues described its discovery in twenty twenty-five. Human receptor assays found twelve times greater potency at the amylin-one receptor than at the calcitonin receptor.
That is a laboratory measurement. It does not mean twelve times more weight loss, or prove better tolerability in patients.
Liana Billings and colleagues studied two hundred sixty-three adults for forty-eight weeks in a randomized phase two trial. Participants had obesity, or overweight with a related condition, without type two diabetes.
Estimated average weight reductions ranged from nine point five to twenty point one percent across six active groups, versus zero point four percent with placebo. These estimates assume participants remained on treatment. Weight loss is only part of the picture. Tolerability matters too.
Gastrointestinal symptoms and fatigue were common. Slower dose escalation was associated with fewer of these events. Long-term safety and sustained benefit remain research questions.
As of October fourteen, twenty twenty-six, eloralintide remains investigational, with phase three studies underway. Tirzepatide combination results are separate evidence. Next: survodutide. The next chapter depends on longer-term evidence.
Peptides in 2. World Peptide Foundation. Every experience matters.
